Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis.
Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes and cardiovascular deaths. It is the leading cause of morbidity and mortality in the industrialized world. Plaque composition, rather than luminal stenosis, is recognized as the major determinant of this disease. Since tissue factor is found within atheroma and also in the bloodstream of atherosclerotic patients, it likely plays a key role in determining both plaque and blood thrombogenicity. Ongoing clinical and preclinical studies are evaluating the therapeutic possibilities of specific inhibition of the tissue factor pathway. Here, we will review the role of tissue factor in atherothrombosis and therapeutic applications.
Viles-Gonzalez
Juan F
JF
Cardiovascular Biology Research Laboratory, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York 10029, USA.
Anand
Sunil X
SX
Zafar
M Urooj
MU
Fuster
Valentin
V
Badimon
Juan J
JJ
D001161:Arteriosclerosis / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D005167:Factor VII / Q000037:antagonists & inhibitors; D005170:Factor X / Q000037:antagonists & inhibitors; D006801:Humans; D013917:Thrombin / Q000037:antagonists & inhibitors; D013925:Thromboplastin / Q000378:metabolism*
D005167:Factor VII; D005170:Factor X; D013925:Thromboplastin; D013917:Thrombin